[
  {
    "ts": null,
    "headline": "Dividend Stocks Have Slumped. Why UPS and Others May Bounce Back.",
    "summary": "Dividend Stocks Have Slumped. Why UPS and Others May Bounce Back.",
    "url": "https://finnhub.io/api/news?id=82b574836e86463a11038e59d399f7a9c7fc6be94ee22a5c873860bebbb9c457",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737468540,
      "headline": "Dividend Stocks Have Slumped. Why UPS and Others May Bounce Back.",
      "id": 132459243,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Dividend Stocks Have Slumped. Why UPS and Others May Bounce Back.",
      "url": "https://finnhub.io/api/news?id=82b574836e86463a11038e59d399f7a9c7fc6be94ee22a5c873860bebbb9c457"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : European Commission approves LAZCLUZE®▼ (lazertinib) in combination with RYBREVANT®▼ (amivantamab) for the first line treatment of patients with EGFR mutated advanced non small cell lung cancer",
    "summary": "FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY For Immediate Release ...",
    "url": "https://finnhub.io/api/news?id=f2d07c934bdff5bbe79486007073681510f17ccf57c9fd5092763986905c7763",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737456070,
      "headline": "Johnson & Johnson : European Commission approves LAZCLUZE®▼ (lazertinib) in combination with RYBREVANT®▼ (amivantamab) for the first line treatment of patients with EGFR mutated advanced non small cell lung cancer",
      "id": 132436617,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY For Immediate Release ...",
      "url": "https://finnhub.io/api/news?id=f2d07c934bdff5bbe79486007073681510f17ccf57c9fd5092763986905c7763"
    }
  },
  {
    "ts": null,
    "headline": "J&J: FDA approves Spravato spray for depression",
    "summary": "Johnson & Johnson announces that the FDA has approved a supplemental application for Spravato nasal spray, as the first monotherapy for adults with major depression resistant to at least two oral...",
    "url": "https://finnhub.io/api/news?id=5c018ed1f1e883edc76357adbe3de70ce3b83afa8ef7d33ba4b7247edb7dcfa2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737452657,
      "headline": "J&J: FDA approves Spravato spray for depression",
      "id": 132436357,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces that the FDA has approved a supplemental application for Spravato nasal spray, as the first monotherapy for adults with major depression resistant to at least two oral...",
      "url": "https://finnhub.io/api/news?id=5c018ed1f1e883edc76357adbe3de70ce3b83afa8ef7d33ba4b7247edb7dcfa2"
    }
  },
  {
    "ts": null,
    "headline": "J&J: EU approves Lazcluze for lung cancer treatment",
    "summary": "J&J announces that the European Commission has approved the marketing authorization of Lazcluze in combination with Rybrevant for the first-line treatment of adult patients with advanced non-small...",
    "url": "https://finnhub.io/api/news?id=ecb38ac055da7caa3cb1a8a0cc61aaf1d087c323953e52c95391661c86cece35",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737450971,
      "headline": "J&J: EU approves Lazcluze for lung cancer treatment",
      "id": 132436215,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "J&J announces that the European Commission has approved the marketing authorization of Lazcluze in combination with Rybrevant for the first-line treatment of adult patients with advanced non-small...",
      "url": "https://finnhub.io/api/news?id=ecb38ac055da7caa3cb1a8a0cc61aaf1d087c323953e52c95391661c86cece35"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Gets FDA OK For Spravato as Monotherapy",
    "summary": "By Colin Kellaher Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on...",
    "url": "https://finnhub.io/api/news?id=154bde4958f3fc1a07db5def6a782235eea63652fa1f18d8e89971a0f54eae63",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737449897,
      "headline": "Johnson & Johnson Gets FDA OK For Spravato as Monotherapy",
      "id": 132436087,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on...",
      "url": "https://finnhub.io/api/news?id=154bde4958f3fc1a07db5def6a782235eea63652fa1f18d8e89971a0f54eae63"
    }
  }
]